II 

111TH CONGRESS 

2D SESSION S. 3031 

To authorize Drug Free Communities enhancement grants to address major 

emerging drug issues or local drug crises. 

IN THE SENATE OF THE UNITED STATES 

FEBRUARY 24, 2010 

Mr. LEAHY (for himself and Mr. GRASSLEY) introduced the following bill; 

which was read twice and referred to the Committee on the Judiciary 

A BILL 

To authorize Drug Free Communities enhancement grants 

to address major emerging drug issues or local drug crises. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Drug Free Commu5 nities Enhancement Act of 2010’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds the following: 

8 (1) The epidemiology of drug use indicates that 

9 emerging drug trends increase over a short period of 

10 time and tend to cluster in discrete geographic 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•S 3031 IS

1 areas. Historical evidence shows that emerging local 

2 drug issues and crises can be stopped or mitigated 

3 before they spread to other areas, if they are identi4 fied quickly and addressed in a comprehensive multi5 sector manner. 

6 (2) Federal investments in drug prevention 

7 should not be solely based on national data and 

8 trends, but must be flexible enough to address 

9 emerging local problems and local drug crises before 

10 they become national trends. 

11 (3) Successful drug prevention must be based 

12 on local data and involve multiple community sectors 

13 in planning and implementing specifically targeted 

14 strategies that respond to the unique drug problems 

15 of the community. 

16 (4) Data and outcomes show that effective com17 munity coalitions can markedly reduce local drug 

18 use rates for drugs such as marijuana and inhalants 

19 among school-aged youth. 

20 (5) Community coalitions are singularly situ21 ated to deal with emerging drug issues and local 

22 drug crises, such as methamphetamine, cheese (a 

23 mixture of black tar heroin and Tylenol PM), and 

24 prescription and non-prescription drug abuse be25 cause the community coalitions are organized, data 


smartinez on DSKB9S0YB1PROD with BILLS
3 

•S 3031 IS

1 driven, and take a comprehensive, multi-sector ap2 proach to solving and addressing locally identified 

3 drug problems. 

4 (6) Providing enhancement grants to coalitions 

5 to address emerging local drug issues or local drug 

6 crises is a cost effective way to deal with these drug 

7 issues. This approach builds on existing infrastruc8 tures with proven results that include all of the rel9 evant community sectors needed to comprehensively 

10 address specific emerging drug issues and crises, 

11 and guards against using Federal funding to create 

12 duplicative community based infrastructures for sub13 stance abuse prevention. 

14 SEC. 3. COMMUNITY-BASED COALITION ENHANCEMENT 

15 GRANTS TO ADDRESS EMERGING DRUG 

16 ISSUES OR LOCAL DRUG CRISES. 

17 (a) DEFINITIONS.—In this section— 

18 (1) the term ‘‘Director’’ means the Director of 

19 the Office of National Drug Control Policy; 

20 (2) the term ‘‘drug’’ means— 

21 (A) a substance listed on schedule I, II, 

22 III, IV, or V of section 202 of the Controlled 

23 Substances Act (21 U.S.C. 812(c)); 

24 (B) inhalants; 


smartinez on DSKB9S0YB1PROD with BILLS
4 

•S 3031 IS

1 (C) if used in a manner that is illegal, a 

2 prescription or over the counter drug or medi3 cine; and 

4 (D) another mind altering substance with 

5 the potential for abuse, as determined by the 

6 Director, not listed on a schedule of section 

7 202(c) of the Controlled Substance Act (21 

8 U.S.C. 812(c)); 

9 (3) the term ‘‘emerging local drug issue’’ 

10 means, with respect to the area served by an eligible 

11 entity, a sudden increase in the use or abuse of a 

12 particular drug in the community, as documented by 

13 local data; 

14 (4) the term ‘‘local drug crisis’’ means, with re15 spect to the area served by an eligible entity, the use 

16 of a specific drug in the area at levels that are sig17 nificantly higher than the national average, over a 

18 sustained period of time, as documented by local 

19 data; and 

20 (5) the term ‘‘eligible entity’’ means an organi21 zation that— 

22 (A) is receiving or has received a grant 

23 under chapter 2 of title I of the National Nar24 cotics Leadership Act of 1988 (21 U.S.C. 1521 


smartinez on DSKB9S0YB1PROD with BILLS
5 

•S 3031 IS

1 et seq.) (commonly known as the Drug-Free 

2 Communities Act of 1997); and 

3 (B) has documented, using local data— 

4 (i) for an emerging local drug issue— 

5 (I) rates of drug use and abuse 

6 above the national average, as deter7 mined by the Director (including ap8 propriate consideration of the Moni9 toring of the Future Survey published 

10 by the Department of Health and 

11 Human Services), for comparable time 

12 periods; or 

13 (II) if national data is not avail14 able, at the discretion of the Director, 

15 high rates of drug use or abuse based 

16 solely on valid local data; or 

17 (ii) for a local drug crisis— 

18 (I) rates of use and abuse for a 

19 specific drug at levels that are signifi20 cantly higher than the national aver21 age, as determined by the Director 

22 (including appropriate consideration 

23 of the Monitoring of the Future Sur24 vey published by the Department of 

25 Health and Human Services and the 


smartinez on DSKB9S0YB1PROD with BILLS
6 

•S 3031 IS

1 National Survey on Drug Use and 

2 Health by the Substance Abuse and 

3 Mental Health Service Administra4 tion); and 

5 (II) rates of use and abuse for a 

6 specific drug that continue over a sus7 tained period of time, as determined 

8 by the Director. 

9 (b) AUTHORIZATION OF PROGRAM.—The Director 

10 may make enhancement grants to eligible entities to im11 plement comprehensive community-wide strategies that 

12 address emerging local drug issues or local drug crises 

13 within the area served by the eligible entity. 

14 (c) APPLICATION.— 

15 (1) IN GENERAL.—An eligible entity desiring an 

16 enhancement grant under this section shall submit 

17 an application to the Director at such time, in such 

18 manner, and accompanied by such information as 

19 the Director may require. 

20 (2) CRITERIA.—As part of an application for a 

21 grant under this section, the Director shall require 

22 an eligible entity to submit a detailed, comprehen23 sive, multi-sector plan for addressing the emerging 

24 local drug issue or local drug crises within the area 

25 served by the eligible entity. 


smartinez on DSKB9S0YB1PROD with BILLS
7 

•S 3031 IS

1 (d) USES OF FUNDS.—A grant under this section 

2 shall be used to— 

3 (1) implement comprehensive, community-wide 

4 prevention strategies to address an emerging local 

5 drug issue or drug crises in the area served by an 

6 eligible entity, in accordance with the plan submitted 

7 under subsection (c)(2); and 

8 (2) obtain specialized training and technical as9 sistance from the entity receiving a grant under sec10 tion 4 of Public Law 107–82 (21 U.S.C. 1521 note). 

11 (e) GRANT AMOUNTS.— 

12 (1) IN GENERAL.—The total amount of grant 

13 funds awarded to an eligible entity for a fiscal year 

14 may not exceed the amount of non-Federal funds 

15 raised by the eligible entity, including in-kind con16 tributions, for that fiscal year. 

17 (2) GRANT AWARDS.—A grant under this sec18 tion shall— 

19 (A) be made for a period of not more than 

20 4 years; and 

21 (B) be for not more than $75,000 per 

22 year. 

23 (f) SUPPLEMENT NOT SUPPLANT.—Grant funds pro24 vided under this section shall be used to supplement, not 


smartinez on DSKB9S0YB1PROD with BILLS
8 

•S 3031 IS

1 supplant, Federal and non-Federal funds available for car2 rying out the activities described in this section. 

3 (g) EVALUATION.—A grant under this section shall 

4 be subject to the same evaluation requirements and proce5 dures as the evaluation requirements and procedures im6 posed on the recipient of a grant under chapter 2 of title 

7 I of the National Narcotics Leadership Act of 1988 (21 

8 U.S.C. 1521 et seq.) (commonly known as the Drug-Free 

9 Communities Act of 1997). 

10 (h) ADMINISTRATIVE EXPENSES.—Not more than 5 

11 percent of the amount appropriated to carry out this sec12 tion for any fiscal year may be used by the Director for 

13 administrative expenses. 

14 (i) AUTHORIZATION OF APPROPRIATIONS.—There 

15 are authorized to be appropriated $5,000,000 for each of 

16 fiscal years 2011 through 2015 to carry out this section. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS